After a series of moves that have soured investors and raised questions about its strategy, Teva Pharmaceuticals announced Erez Vigodman is stepping down as chief executive.
The change follows a tumultuous stretch for the drug maker, which is one of the world’s largest purveyors of generic medicines, but has struggled on numerous fronts and increasingly prompted speculation that Vigodman would be shown the door. Dr. Yitzhak Peterburg, a Teva board member who once headed the branded-medicines group will replace him on an interim basis.
About the Author Reprints
